Global ETD Search

Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.

Results

Showing 1 to 20 of 127 for “"PCSK9"”.

  1. IMPACT OF PCSK9 ON EXTRAHEPATIC TISSUES

    … proproteina convertasi subtilisina kexin tipo 9 (PCSK9) è una glicoproteina di 692 amminoacidi che appartiene alla famiglia delle proproteine convertasi. È prodotta principalmente dal fegato dal quale viene secreta nel torrente circolatorio. PCSK9 interagisce con diversi recettori della famiglia …

    milano Repository record for IMPACT OF PCSK9 ON EXTRAHEPATIC TISSUES (opens in a new tab)

  2. Ο ρόλος της PCSK9 στην αθηροθρόμβωση

    Background-Purpose: PCSK9 is a serine protease which, in addition to its major role in endosomal and lysosomal degradation of the LDL receptor, which results in increased plasma LDL-cholesterol levels, exhibits several LDL receptor-independent actions on a variety of cell types, including …

    greece Repository record for Ο ρόλος της PCSK9 στην αθηροθρόμβωση (opens in a new tab)

  3. MACROPHAGE EXPRESSION OF PCSK9 INFLUENCES ATHEROSCLEROSIS DEVELOPMENT

    Proprotein Convertase Subtilisin/Kexin 9 (PCSK9) regulates low‐density lipoprotein (LDL) cholesterol levels by binding and degrading hepatic LDL receptor (LDLR), thus promoting atherosclerosis. Little is known of PCSK9 effect in macrophages and whether this contributes to the development of the …

    milano Repository record for MACROPHAGE EXPRESSION OF PCSK9 INFLUENCES ATHEROSCLEROSIS DEVELOPMENT (opens in a new tab)

  4. PCSK9 inhibitors as a therapy for hypercholesterolemia

    … Currently, two monoclonal antibodies inhibiting PCSK9 are approved for use; these monoclonal antibodies work well in conjunction with other medications for hypercholesterolemia, such as statins or ezetimibe, and are equivalent in efficacy with high dose statins. Investigation of PCSK9 inhibitors …

    bu Repository record for PCSK9 inhibitors as a therapy for hypercholesterolemia (opens in a new tab)

  5. Ο ρόλος του συστήματος PCSK9/LDLR στην NAFLD

    … (Proprotein convertase subtilisin/kexin type 9 – PCSK9) και του υποδοχέα για τις λιποπρωτεΐνες χαμηλής πυκνότητας (Low-density lipoprotein receptor – LDL-R), και των διαφόρων σταδίων της NAFLD. Ταυτόχρονα μελετήθηκαν οι πιθανές αλληλεπιδράσεις ανθρωπομετρικών και εργαστηριακών παραμέτρων, με τα …

    athens Repository record for Ο ρόλος του συστήματος PCSK9/LDLR στην NAFLD (opens in a new tab)

  6. PCSK9 Inhibition and Coronary Artery Disease in Mice

    … proprotein convertase subtilisin/kexin type 9 (PCSK9) is widely known for its role in enhancing LDL receptor (LDLR)-mediated cholesterol lowering when the LDLR-apolipoprotein E (APOE) axis is intact and protecting against atherosclerosis progression by reducing plasma cholesterol levels. In this …

    mcmaster Repository record for PCSK9 Inhibition and Coronary Artery Disease in Mice (opens in a new tab)

  7. Importance of phosphorylation in PCSK9 processing, stability and function

    Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a secreted glycoprotein regulating the degradation of low density lipoprotein receptor. Single nucleotide polymorphisms in PCSK9 associate with both hyper- and hypo-cholesterolemia; studies show significant reduction in risk of coronary heart …

    ottawa-retro Repository record for Importance of phosphorylation in PCSK9 processing, stability and function (opens in a new tab)

  8. DECIPHERING THE ROLE OF ADIPOKINES ON PCSK9 REGULATION: EXPERIMENTAL EVIDENCE

    … of proprotein convertase subtilisin/kexin 9 (PCSK9), the key regulator of low-density lipoprotein receptor and also involved in triglycerides (TG) metabolism. This latter evidence come from genetic studies reporting high levels of TG in patients with gain of function (GOF) mutations in PCSK9 …

    milano Repository record for DECIPHERING THE ROLE OF ADIPOKINES ON PCSK9 REGULATION: EXPERIMENTAL EVIDENCE (opens in a new tab)

  9. PCSK9 AND INFLAMMATION: IN VITRO STUDY ON HEPATOCYTES AND MACROPHAGES

    … proprotein convertase subtilisin kexin type 9 (PCSK9) expression in hepatic HepG2 cell line, through the activation of suppressor of cytokine signaling 3 (SOCS3): Background. The suppressor of cytokine signaling (SOCS) proteins are negative regulators of the JAK/STAT pathway activated by …

    milano Repository record for PCSK9 AND INFLAMMATION: IN VITRO STUDY ON HEPATOCYTES AND MACROPHAGES (opens in a new tab)

  10. The Regulation of PCSK9 Structure and Function Through Lipoprotein Interactions

    Proprotein convertase subtilisin / kexin type 9 (PCSK9) is a negative regulator of the low-density lipoprotein receptor, and PCSK9 inhibition has become an important cholesterol-lowering therapeutic strategy. PCSK9 also associates with LDL particles, and evidence suggests that the activity of PCSK9 …

    ottawa-retro Repository record for The Regulation of PCSK9 Structure and Function Through Lipoprotein Interactions (opens in a new tab)

  11. PCSK9 REGULATES LDLR-MEDIATED UPTAKE OF LIPOPOLYSACCHARIDE AND LIPOTEICHOIC ACID

    … Proprotein convertase subtilisin/kexin type 9 (PCSK9) regulates uptake of LPS by hepatocytes, but it is unknown whether LTA uptake is similarly regulated. Therefore, our objectives were to characterize the PCSK9-regulated pathway of bacterial lipid uptake by hepatocytes by identifying whether …

    mcmaster Repository record for PCSK9 REGULATES LDLR-MEDIATED UPTAKE OF LIPOPOLYSACCHARIDE AND LIPOTEICHOIC ACID (opens in a new tab)

  12. PCSK9 AS A DRIVER OF LIPID METABOLISM AND KIDNEY DISEASE

    … proprotein convertase subtilisin/kexin type-9 (PCSK9) was identified as the third locus of familial hypercholesterolemia and was further characterized for its ability to enhance the degradation of the low-density lipoprotein receptor (LDLR). Since this seminal discovery, the development of …

    mcmaster Repository record for PCSK9 AS A DRIVER OF LIPID METABOLISM AND KIDNEY DISEASE (opens in a new tab)

  13. Regulation of LDL-Cholesterol by Circulating PCSK9 and its Natural Variants

    … proprotein convertase subtilisin/kexin type-9 (PCSK9) acts as a binding chaperone to mediate endo-lysosomal degradation of cell surface low-density lipoprotein receptor (LDLR). Gain-of-function (GOF) mutations in PCSK9 are causative for autosomal dominant hypercholesterolemia (ADH). An acidic …

    ottawa-retro Repository record for Regulation of LDL-Cholesterol by Circulating PCSK9 and its Natural Variants (opens in a new tab)

  14. Characterization of PCSK9-mediated LDLR Degradation in Hepatic and Fibroblast Cells

    … proprotein convertase subtilisin/kexin type 9 (PCSK9) mediates degradation of low-density lipoprotein receptors (LDLR) indicates a critical role in LDL metabolism. PCSK9 is a secreted protein that binds to the epidermal growth factor-like (EGF)-A domain of LDLR and directs the receptor for …

    ottawa-retro Repository record for Characterization of PCSK9-mediated LDLR Degradation in Hepatic and Fibroblast Cells (opens in a new tab)

  15. Quantitative Subcellular Analysis of the Effects of the Enigmatic Protein PCSK9

    PCSK9 is the third gene implicated in autosomal dominant hypercholesterolemia, due to its role in promoting the degradation of the low density lipoprotein receptor (LDLR). Little is known regarding the mechanism by which it promotes the degradation of LDLR, nor the effects PCSK9 has on other …

    ottawa-retro Repository record for Quantitative Subcellular Analysis of the Effects of the Enigmatic Protein PCSK9 (opens in a new tab)

  16. Investigation of PCSK9 and Peripherin Levels in Multiple Sclerosis Disease Progression

    … A proprotein convertase subtilisin/kexin type 9 (PCSK9) enzyme was reported to promote the intra-lysosomal degradation of the LDL receptors and increases its plasma level. In clinical trials, PCSK9 inhibitors showed potent reduction in the LDL-C levels without affecting the cholesterol de novo …

    buffalo Repository record for Investigation of PCSK9 and Peripherin Levels in Multiple Sclerosis Disease Progression (opens in a new tab)

  17. An investigation into statins, PCSK9 inhibitors, and other current cholesterol treatments

    … concurrence with statins. Drug classes such as PCSK9 inhibitors, ApoB inhibitors, MTP inhibitors, and thyromimetics have all been explored with varying success. Each of these potential therapies has a separate mechanism of action, allowing for modulation in conjunction with statins. PCSK9 …

    bu Repository record for An investigation into statins, PCSK9 inhibitors, and other current cholesterol treatments (opens in a new tab)

  18. The role of lipids and PCSK9 in long-term outcomes of sepsis

    … proprotein convertase subtilisin-kexin type 9 (PCSK9),a major regulator of LDL plasma levels and LDL receptor metabolism in the long-term outcomes of sepsis was evaluated through: i) analysis of the impact of PCSK9 loss-of-function genotype in a composite outcome composed by 1-year death or …

    ubc Repository record for The role of lipids and PCSK9 in long-term outcomes of sepsis (opens in a new tab) Download PDF for The role of lipids and PCSK9 in long-term outcomes of sepsis (opens in a new tab)

  19. PCSK9 (PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9)AND GLUCOSE METABOLISM: WHICH CONNECTION?

    PCSK9 (proprotein convertase subtilisin/kexin type 9) and glucose metabolism: which connection? Background: PCSK9 (proprotein convertase subtilisin/kexin type 9), is a protein, mainly synthesized and secreted by the liver, which binds to specific target proteins and escorts them towards lysosomes …

    milano Repository record for PCSK9 (PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9)AND GLUCOSE METABOLISM: WHICH CONNECTION? (opens in a new tab)

  20. Udział Białka PCSK9 w patogenezie miażdżycy u osób z ostrym zespołem wieńcowym

    Odkąd odkryto, że PCSK9 (ang. Proprotein Convertase Subtilisin/Kexin type 9) degraduje receptory LDL, stało się ono jednym z głównych obiektów badań nad miażdżycą. Celem niniejszej pracy było określenie udziału białka PCSK9 w patogenezie miażdżycy u 102 osób z ostrym zespołem wieńcowym (OZW), przed …

    amu-pl Repository record for Udział Białka PCSK9 w patogenezie miażdżycy u osób z ostrym zespołem wieńcowym (opens in a new tab)

Page 1 of 7